Astrazeneca (AZN) EBT Margin (2009 - 2026)

Astrazeneca has reported EBT Margin for 18 years, with the latest figure at 18.19% in Q2 2026.

• On a quarterly basis, EBT Margin fell 345.0% year-over-year to 18.19% in Q2 2026; TTM through Jun 2026 was 39.26%, a 2122.0% increase from a year earlier, with the FY2025 full-year figure at 21.15%, up 480.0% from the prior year.
• EBT Margin was 18.19% for Q2 2026 at Astrazeneca, down from 25.73% in the prior quarter.
• The five-year high for EBT Margin was 90.99% in Q4 2025, with the low at 2.32% in Q2 2022.
• Average EBT Margin over 5 years is 20.32%, with a median of 18.51% recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: EBT Margin sank 1730 bps in 2022, then jumped 7916 bps in 2025.
• Over 5 years, EBT Margin stood at 6.94% in 2022, then jumped by 166 bps to 18.49% in 2023, then sank by 36 bps to 11.84% in 2024, then soared by 669 bps to 90.99% in 2025, then tumbled by 80 bps to 18.19% in 2026.
• The last three EBT Margin figures came in at 18.19% (Q2 2026), 25.73% (Q1 2026), and 90.99% (Q4 2025), per Business Quant data.